Project Grant HT94252510361
Award Date
5/1/25
Completion Date
4/30/28
Dollars Obligated
$763K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
New York, NY 10022, USA
Similar Awards
This federal Project Grant award in the amount of $1,356,000.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award, with a performance period from November 1, 2024 to October 31, 2028, supports the "Restoration of Clear Cell Renal Cell Carcinoma Tumorigenicity by Cell Reprogramming" research project conducted by the Weill Medical College of Cornell University, a prestigious academic medical...
The federal Project Grant award of $847,501.00, funded by the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by Weill Medical College of Cornell University to investigate the role of BCL-XL in breast cancer metastasis and therapy. The award, effective from August 1, 2024 to July 31, 2027, will enable the institution to perform advanced biomedical research focused on understanding the cellular...
The Department of the Army Medical Command awarded a $762,750 Project Grant to Weill Medical College of Cornell University under the Military Medical Research and Development program (CFDA 12.420). The three-year grant will fund research on perk-driven stress responses that regulate dendritic cell function in ovarian cancer. Through June 2024, Weill Medical College will investigate how stress responses impact immune cell activity and how this relationship influences ovarian cancer progression....
This federal Project Grant award, ID HT94252410310, was issued by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award, totaling $1,518,817.00, supports research by Weill Medical College of Cornell University to characterize 3'-UTR biology as a mechanism of therapy response in high-risk prostate cancer. The 3-year project, with a performance period from Sep 30, 2024 to Sep 29, 2027, aims to advance the understanding of cellular mechanisms...
The Department of the Army Medical Command awarded a $1,016,998 Project Grant to the Joan & Sanford I Weill Medical College of Cornell University to support research titled "Harnessing Dietary N-3 Fatty Acids to Unleash Protective Immunity Against Ovarian Cancer." The grant period runs from June 1, 2021 through May 31, 2024. The funding supports research under the Military Medical Research and Development program (CFDA 12.420), which aims to transform military and public health...
This federal Project Grant award of $808,141, issued by the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program, supports research targeting inflammatory pathways in breast cancer brain metastases. The award provides funding to Weill Medical College of Cornell University, a leading academic medical institution, to conduct research on using anti-VEGF ultrasmall particle therapy for the treatment of edema and radiation necrosis. The...
The U.S. Defense Health Agency awarded a $1,522,278 Project Grant to Weill Medical College of Cornell University on September 30, 2024 under the Military Medical Research and Development program (CFDA 12.420). The grant supports a research project titled "Decoding Bone Metastasis in Prostate Cancer: A Multimodal Approach Integrating Genomics and Imaging Data." The project aims to advance scientific understanding and improve treatment of bone metastasis in prostate cancer patients...
This federal Project Grant award, valued at $358,264.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award aims to support research targeting inflammatory pathways in breast cancer brain metastases to develop treatments for edema and radiation necrosis using anti-VEGF ultrasmall particle therapy. This work will be conducted by Cornell University's Office of Sponsored Programs from February 1, 2025 to...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $677,998 to Weill Medical College of Cornell University to conduct research titled "TARGETING ECDNA TO REVERSE THERAPY-RESISTANCE IN UROTHELIAL CANCER". The project aims to investigate innovative approaches to targeting extrachromosomal DNA (ecDNA) in order to reverse therapy resistance in urothelial (bladder) cancer. The award period runs...
This federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $312,610 to Weill Medical College of Cornell University to support research on the role of functional factors in androgen receptor (AR) reprogramming and progression of prostate cancer. The research aims to investigate innovative approaches to disease prevention, diagnosis, treatment, and management, with a focus on conditions...